Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2018

Publisher Name :
Date: 16-Oct-2018
No. of pages: 73

Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2018

Summary

Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 22 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Transforming Growth Factor Beta 1- Pipeline Review, H2 2018, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-ß1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 6 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Respiratory, Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology, Gastrointestinal, Immunology, Ophthalmology, Central Nervous System, Genetic Disorders, Hematological Disorders and Metabolic Disorders which include indications Fibrosis, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis, Osteoarthritis, Anemia, Bile Duct Cancer (Cholangiocarcinoma), Bone Disorders, Breast Cancer, Cholangitis, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hyperalgesia, Hypertrophic Scars, Inflammation, Lung Adenocarcinoma, Metastatic Breast Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Open-Angle Glaucoma, Osteogenesis Imperfecta, Pancreatitis Pain, Peripheral Artery Occlusive Disease (PAOD), Primary Sclerosing Cholangitis, Proliferative Vitreoretinopathy (PVR), Pulmonary Fibrosis, Pulmonary Hypertension, Scar, Solid Tumor, Squamous Cell Carcinoma, Systemic Sclerosis (Scleroderma) and Wounds.

Furthermore, this report also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)

- The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Transforming Growth Factor Beta 1 (TGFB1) - Overview
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development
AlfaSigma SpA
Ensol Biosciences Inc
Forbius
Genzyme Corp
Huabo Biopharm Co Ltd
Isarna Therapeutics GmbH
Johnson & Johnson
Novartis AG
Scholar Rock Inc
Sirnaomics Inc
Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles
Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVID-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-1021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Engedi-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluorofenidone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fresolimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-1047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-1106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TGF Beta1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TGFB1 for Oncology, Gastrointestinal and Genito Urinary System and Sex Hormones Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody 1 to Inhibit TGFB1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGF-Beta-1 for Chronic Pancreatitis Pain and Hyperalgesia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGFB1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit TGF Beta 1 for Squamous Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TGFB1 for Camurati-Engelmann Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TGFB1 for Idiopathic Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulodexide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XOMA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transforming Growth Factor Beta 1 (TGFB1) - Dormant Products
Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products
Transforming Growth Factor Beta 1 (TGFB1) - Product Development Milestones
Featured News & Press Releases
Oct 01, 2018: Present preclinical data highlighting the role of TGFß1inhibition in overcoming checkpoint resistance at the SITC Annual Meeting
Jul 19, 2018: Toray Announces Initiation of Phase 1 Clinical Trial of TRK-250 for Patients with Idiopathic Pulmonary Fibrosis
Feb 17, 2018: AVID200 Program Featured in an Oral Presentation at the 5th Systemic Sclerosis World Congress and Received an Award for One of the Most Original Works Presented at the Congress
Feb 02, 2018: Formation Biologics Announces Award of $675,000 BioCanRx Grant to Support Development of AVID200
Dec 06, 2017: Sirnaomics' Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for Treatment of Cholangiocarcinoma
Oct 06, 2017: Sirnaomics Publishes Results Showing Dual Targeting of TGF-ß1 and COX-2 Reduces Human Skin Hypertrophic Scar through Activation of Fibroblast Apoptosis
Aug 01, 2017: Sirnaomics Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for the Treatment of Primary Sclerosing Cholangitis
Jun 15, 2017: Sirnaomics Advances Leading siRNA Therapeutic Candidate, STP705, for Treatment of Liver Fibrosis
May 01, 2017: Sirnaomics Received IND Approval from CFDA for Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
Feb 06, 2017: Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
Jan 03, 2017: Haiyao Obtains Clinical Trial Approval for Fluorofenidone from General Administration of Pharmacy, China
Nov 07, 2016: Sirnaomics Received Green Light from US FDA for a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
Jul 14, 2015: Scholar Rock Presents Preclinical Data for First Demonstration of Novel Pharmacological Approach to Targeting the TGFß1 Latent Complex
Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US
Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AlfaSigma SpA, H2 2018
Pipeline by Ensol Biosciences Inc, H2 2018
Pipeline by Forbius, H2 2018
Pipeline by Genzyme Corp, H2 2018
Pipeline by Huabo Biopharm Co Ltd, H2 2018
Pipeline by Isarna Therapeutics GmbH, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Scholar Rock Inc, H2 2018
Pipeline by Sirnaomics Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018
  • Global Cough Drops Market Insights, Forecast to 2025
    Published: 24-May-2019        Price: US 3900 Onwards        Pages: 110
    Cough drops are typically medicated tablet intended to be dissolved slowly in the mouth to temporarily stop coughs and thaty can lubricate and soothe irritated tissues of the throat. The global Cough Drops market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cough Drops market based on company, product type, end user and key re......
  • Global Transdermal Drug Delivery Systems Market Insights, Forecast to 2025
    Published: 24-May-2019        Price: US 3900 Onwards        Pages: 123
    Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous mem......
  • Global Platelet Rich Plasma Market Size, Status and Forecast 2019-2025
    Published: 24-May-2019        Price: US 3900 Onwards        Pages: 92
    Platelet rich plasma (PRP) is a blood plasma product in which concentration of platelets is elevated four to eight times than normal blood platelet concentration.PRP is also called platelet rich gel, platelet enriched plasma and platelet enriched gel. In 2018, the global Platelet Rich Plasma market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Platelet Rich Plasma......
  • Global Translational Regenerative Medicine Market Insights, Forecast to 2025
    Published: 24-May-2019        Price: US 4900 Onwards        Pages: 111
    The global Translational Regenerative Medicine market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Translational Regenerative Medicine market based on company, product type, end user and key regions. This report studies the global market size of Translational Regenerative Medicine in key regions like North America, Eur......
  • Global Haemophilia Treatment Market Insights, Forecast to 2025
    Published: 24-May-2019        Price: US 3900 Onwards        Pages: 113
    Haemophilia is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. The global Haemophilia Treatment market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Haemophilia Treatment market based on company, product type, end user and key regions. Th......
  • Global Dendrimers Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 24-May-2019        Price: US 3480 Onwards        Pages: 139
    Scope of the Report: The worldwide market for Dendrimers is expected to grow at a CAGR of roughly over the next five years, will reach million US$ in 2024, from million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the Dendrimers in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. ......
  • Global Filgrastim Market Insights, Forecast to 2025
    Published: 24-May-2019        Price: US 3900 Onwards        Pages: 113
    Granulocyte - colony stimulating factor (G-CSF) is another name for filgrastim. In some cases, health care professionals may use the trade name Neupogen, Granix or Zarxio when referring to the generic drug name filgrastim. The global Filgrastim market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Filgrastim market based on comp......
  • Global Pulmonary Arterial Hypertension Treatment Market Insights, Forecast to 2025
    Published: 24-May-2019        Price: US 3900 Onwards        Pages: 111
    Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death. The global Pulmonary Arterial Hypertension Treatment market is valued at xx millio......
  • Global Tyrosine Protein Kinase BTK Market Insights, Forecast to 2025
    Published: 24-May-2019        Price: US 3900 Onwards        Pages: 114
    This report studies the Tyrosine Protein Kinase BTK market, Bruton's tyrosine kinase (abbreviated Btk or BTK) also known as tyrosine-protein kinase BTK is an enzyme that in humans is encoded by the BTK gene. BTK is a kinase that plays a crucial role in B lymphocytes development. The global Tyrosine Protein Kinase BTK market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to de......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs